Testing patient blood samples for diagnostic or prognostic microRNA markers is the "next big thing" for Rosetta Genomics.

CEO Ken Berlin said last week that the company is developing a number of tests that can be performed on bodily fluids from patients. Should Rosetta successfully commercialize these tests, the Rehovot, Israel-based molecular diagnostics firm believes it could address other lucrative markets.

The company already offers a menu of oncology tests that are performed on biopsy samples.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.